Using mass spectrometry to monitor multiple myeloma
Official title: Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
Run by Zhujiang Hospital · NCT05686447 · Data updated 2026-11-12
This study is testing a new way to use mass spectrometry to see if it can help doctors better detect and monitor multiple myeloma in patients by analyzing their blood samples.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | January 1, 2023 |
| Main results expected | June 1, 2026 |
| Study ends | July 31, 2026 |
| Registry record updated | April 6, 2025 |
| Trial ID | NCT05686447 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with multiple myeloma who have serum samples available for analysis.
✕Probably not a fit
Patients with incomplete sample information or those whose samples do not meet collection and storage requirements may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to utilize MALDI-TOF mass spectrometry to detect, characterize, and quantify M-protein in patients with multiple myeloma. By analyzing serum samples, the study seeks to provide a more precise diagnostic tool and monitor treatment responses in a sensitive and specific manner. The approach focuses on improving early diagnosis and risk assessment of multiple myeloma, which currently lacks effective large-scale screening methods. The study will include both diagnosed patients and healthy controls for comparison.
Why it matters
Potential benefit: If successful, this method could lead to earlier diagnosis and better monitoring of treatment responses in multiple myeloma patients.
How similar studies have gone: Other studies have shown promise in using mass spectrometry for protein analysis, indicating potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:(1) Inclusion criteria for cases: Serum samples from related people diagnosed with multiple myeloma were included in MALDI-TOF-MS analysis by serum protein electrophoresis (SPEP), serum immunofixation electrophoresis (IFE), Ig isotype detection and other methods. (2) Inclusion criteria of the controls were as follows: individuals in good health without obvious disease and with normal physical examination report; Avoid people who have not suffered from major chronic diseases in recent years, such as hypertension, diabetes, chronic kidney disease, etc; controls were appropriately selected that matched cases for age and sex. \- Exclusion Criteria: samples with incomplete sample information and untraceable source; Samples whose sample volume is insufficient for testing; Samples that do not meet the requirements for sample collection and storage \-
Where it's running
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Nianyi Zeng
- Email: zengny1@i.smu.edu.cn
- Phone: 13928801657
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How N-glycosylation of light chains affects AL amyloidosis diagnosis and treatment
This project will test whether a sugar modification called N-glycosylation on immunoglobulin light chains helps cause disease or changes how AL amyloidosis and related monoclonal gammopathies behave in adults.
-
Analyzing gut microbiota in patients with monoclonal gammopathy
This study is trying to see how the gut bacteria of people with monoclonal gammopathy differ from those without the condition to help find new ways to diagnose and treat it.
-
Investigating gut microbiota and immune function in monoclonal gammopathy patients
This study looks at the gut bacteria and immune system in patients with monoclonal gammopathy to see how they might be affected, especially in those with infections.
-
6MW5311 in adults with relapsed or refractory blood cancers
This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma
In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.